Currency in EUR
Last close As at 25/03/2023
— 0.00 (−1.52%)
Quantum Genomics is a Paris-based biotechnology company focused on addressing unmet medical needs.
The global market for cardiovascular drugs is considerable; in 2021 the market for hypertension drugs alone was estimated to be worth c US$13bn. Quantum Genomics has already secured seven licensing deals worldwide (worth up to c US$123m) but has not yet signed an agreement in the key US or EU5 regions. We view the signing of a licensing agreement in these regions as key to maximising the commercial impact of the asset.
Founder & Chairman
Forecast net debt (€m)
Forecast gearing ratio (%)
|52 week high/low||€4.0/€0.1|
Following the announcement that results from the Phase III FRESH study, investigating the use of firibastat in treatment-resistant hypertension (TRH) were non-significant versus placebo, Quantum Genomics has terminated a second, longer-term Phase III trial (REFRESH) in TRH and will stop the development of firibastat in cardiology. The company estimates it will have c €11m after the full discontinuation of cardiology development with which to pursue new opportunities to develop new assets. Our estimates and valuation for Quantum Genomics are under review.
|Y/E Dec||Revenue (€m)||EBITDA (€m)||PBT (€m)||EPS (c)||P/E (x)||P/CF (x)|
Get access to the very latest content matched to your personal investment style.